

Deciphering the Expression of *Klotho*, *Superoxide Dismutase 1*, *Catalase*, *p53*, and *Cyclophilin* Genes in Pathogenesis of Chronic Kidney Disease

Bakhtawar Farooq^{1,2}, Mehwish Iqbal³, Munfoosa Jaffar⁴, Zahid Habib Qureshi⁵,
Muhammad Faisal⁶, Madeeha Shahzad Lodhi^{1*}

ABSTRACT

OBJECTIVE: To analyze the expression of genes involved in OS scavenging defense activation and to understand their contribution to CKD pathogenesis.

METHODOLOGY: A case-control study was conducted among 150 participants in Ibn-e-Sina Hospital, Multan, from January to August 2023. The relative expression of antioxidants, including *Klotho* (KL), *Catalase* (CAT), *Cyclophilin A* (CyPA), tumor protein p53 (p53), and *Superoxide dismutase 1* (SOD1), was quantified using gene-specific primers and real-time qPCR. Data were analyzed by one-way analysis of variance (ANOVA) via GraphPad Prism. The correlation among the KL, CAT, and SOD1 genes was evaluated via matrix scatter plots.

RESULTS: The results show that the relative expression of KL and CAT genes was significantly downregulated in acute kidney injury (AKI) and CKD patients, whereas SOD1 was upregulated in AKI and downregulated in CKD patients compared with controls. The levels of p53 were upregulated by >3-fold in CKD and AKI patients. CyPA was upregulated by >1.5-fold in patients with CKD and AKI. Across CKD stages, the levels of KL and CAT were downregulated, while SOD1 was unaffected. The levels of p53 were >9-fold, 6-fold, and >3-fold upregulated in CKD stages 5 to 3, respectively. CyPA was >1.8-fold upregulated in stages 5 and 4 versus control. The KL gene was positively correlated with the CAT gene.

CONCLUSION: Differential expression levels of KL, CAT, SOD1, p53, and CyPA genes suggest their potential role in mediating OS scavenging, regulation, pathogenesis, and progression of kidney disease.

KEYWORDS: CKD, AKI, Kidney, Disease, Pathogenesis.

INTRODUCTION

Chronic kidney disease (CKD) has become a significant health issue that impacts >10% of the global population¹. Acute kidney injury (AKI) is defined as a sudden reduction in kidney function, whereas CKD is a steady loss of kidney function over time^{2,3}. An estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m² for 3 months indicates CKD, characterized by tubular atrophy, glomerulosclerosis, vascular rarefaction, arteriosclerosis, and nephron loss. Activation of fibrotic and inflammatory pathways, mitochondrial dysfunction, genetics, and cellular

senescence contribute to CKD². High reactive oxygen species (ROS) lead to oxidative stress (OS), which lowers the activity of antioxidative enzymes. This imbalance leads to the oxidation of proteins, nucleic acids, carbohydrates, and lipids, resulting in cell apoptosis and necrosis⁴. Increased ROS in early kidney diseases causes tissue damage via dysregulation linked to AKI and CKD⁵. Approximately 90% of cellular ROS is produced by mitochondria. OS occurs when ROS production exceeds removal, affecting multiple cellular components. As a highly active organ, the kidney is vulnerable to OS-induced damage that can lead to CKD⁶. Defense systems depend on micronutrient intake and antioxidant enzyme production, such as superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX)⁷. CAT, mainly located in the proximal tubule cytoplasm, is crucial for combating OS by regulating ROS, specifically by decomposing hydrogen peroxide (H₂O₂) into water (H₂O) and oxygen (O₂), thus maintaining redox balance in kidney function^{7,8}. Superoxide dismutase (SOD) is another antioxidant that protects cells from OS by converting superoxide radicals into H₂O₂ and O₂, which are subsequently reduced to water by catalase or GPX. SOD is highly expressed in the kidneys and inhibits the oxidative inactivation of nitric oxide (NO)^{7,8}. SODs comprise three isoforms (SOD1, SOD2, SOD3) in the kidney. SOD1 is the most prevalent SOD; its depletion

¹Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan

²Department of Biochemistry, Nishtar Medical University, Multan, Pakistan

³General Medicine Ward-1, Children's Hospital, Multan, Pakistan

⁴Department of Endocrinology and Diabetes, Children's Hospital, Multan, Pakistan

⁵Department of Physiology, Multan Medical and Dental College, Multan, Pakistan

⁶Assistant Professor, Biotechnology, Institute of Plant Breeding and Biotechnology, MNS-University of Agriculture, Multan, Pakistan

Correspondence: madeeha.shahzad@imbb.uol.edu.pk
doi: 10.22442/jlumhs.2026.01377

Received: 20-08-2025
Accepted: 27-02-2026

Revised: 06-02-2026
Online First: 18-03-2026



increases NF- κ B signaling and causes oxidative DNA damage in renal tissues⁷. Klotho (KL) is a transmembrane protein primarily found in healthy kidneys and recognized as an aging-suppressor protein. Its levels decline with age, contributing to kidney function loss and being linked to aging-related diseases, including hypertension, CKD, diabetes, cancer, and cardiovascular diseases⁹. *p53* is a tumor suppressor gene that plays roles in apoptosis, DNA damage repair, senescence, and growth detention¹⁰. *p53* levels remain low in normal cells because its interactions with ubiquitin ligases promote *p53* degradation¹¹. Increased *p53* expression is associated with CKD progression¹². CyPA is a peptidyl-prolyl cis/trans isomerase-active immunophilin. It is widely expressed in cellular proteins, particularly in proximal tubular epithelial cells of the kidney. Changes in its expression and secretion are crucial for various physiological processes and the pathophysiology of kidney-related diseases¹³.

The *KL*, *CAT*, *SOD1*, *p53*, and *CyPA* genes play important roles in kidney function, and their altered expression is associated with CKD pathogenesis. Therefore, this study aimed to analyze the expression of the *KL*, *CAT*, *SOD1*, *p53*, and *CyPA* genes in CKD and AKI patients to investigate their roles in pathogenesis and support early diagnosis and disease control.

METHODOLOGY

Study design

A case-control study was conducted at Ibn-e-Sina Hospital in Multan, Pakistan, from January to August 2023. Informed consent was obtained from all participants in accordance with the Declaration of Helsinki. Patients with dialysis, specific immune therapy, uterine fibroids, cancer, steroid therapy, rheumatoid arthritis, systemic lupus erythematosus, acute infection, septic shock, hypotension, and COVID-19 were excluded from this study. In contrast, patients with diabetes, hypertension, cardiovascular disease, arthritis and glomerulonephritis were included.

Participant selection

150 participants were selected. CKD and AKI were defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. CKD patients were further sub-grouped by stages of the disease via the Modification of Diet in the Renal Disease (MDRD) equation as described by Yang W-C 2023¹⁴. We collected 5 of whole blood samples (biopsy) from all participants by venipuncture into anticoagulant EDTA tubes and stored them at -20°C in a refrigerator for further use.

RNA Extraction

RNA extraction was performed using the Total RNA Purification Micro Kit (Catalogue number 4373872). A 1.5% agarose gel was used to confirm the integrity of the extracted RNA via Bio-Rad agarose gel electrophoresis, and the quantity was measured

using a Thermo Scientific NanoDrop 2000 spectrophotometer.

cDNA synthesis

We converted the extracted RNA to cDNA using the Thermo Scientific RevertAid First Strand cDNA Synthesis Kit (catalogue number K1622) and stored it at -20°C for later use.

Primer designing

Klotho (KL), *Catalase (CAT)*, *Cyclophilin A (CyPA)*, *tumor protein p53 (p53)* and *Superoxide dismutase 1 (SOD1)* genes were selected for Real-time qRT-PCR. *Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)* was used as a housekeeping gene. We used the Primer3Plus web interface (<https://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi>) to design the primers. The genetic sequences of the selected genes were retrieved from NCBI (<http://www.ncbi.nlm.nih.gov/nucleotide>) and are listed in Table I. All the designed primers were then checked for homology and specificity using the BLAST bioinformatics tool (www.basic.northwestern.edu/biotools/oligocalc.html), and mismatches and secondary structure within the primers were avoided.

Table I: Forward and reverse primers to study the expression of selected genes and the housekeeping gene (GAPDH)

Gene	Primer	Sequence
<i>KL</i>	F	GCCACATACTGGATGGTATCAA
	R	ACTGCACTCAGTACACACGGTGA
<i>CAT</i>	F	CGTGCTGAATGAGGAACAGA
	R	AGTCAGGGTGGACCTCAGTG
<i>SOD1</i>	F	GGCAAAGGTGGAAATGAAGA
	R	ACCACAAGCCAAACGACTTC
<i>CyPA</i>	F	TGCCATCGCCAAGGAGTAG
	R	TGCACAGACGGTCACTCAAA
<i>p53</i>	F	CCCCTCCATCCTTTCTTCTC
	R	ATGAGCCAGATCAGGGACTG
<i>GAPDH</i>	F	GGTGGTCTCCTCTGACTTCAACA
	R	ACCAGGAAATGAGCTTGACAAAG

Note: F= Forward Primer, R= Reverse Primer

Gene expression analysis through qRT-PCR

Amplification KIT qRT-PCR was performed to evaluate the expression of *KL*, *CAT*, *SOD1*, and *CyPA* via the 7500 Fast Real-Time PCR System. TaqMan Fast Universal PCR Master Mix was utilized, with each 25 μ L reaction containing 12.5 μ L Maxima SYBR Green/ROX q Master Mix (2X), 0.5 μ M of forward and reverse primers, and water. Finally, 0.5 μ L of cDNA was added to the PCR plate for the RT-PCR program. The initial denaturation step was set at 94 °C for 5 minutes, followed by another 30sec of denaturation at 94 °C. Annealing was performed at 60 °C for 30 sec, and extension was performed at 72 °C for 30 sec. By normalizing to *GAPDH* expression, the relative quantification method $2^{-\Delta\Delta Ct}$ was used to assess the quantification of the target transcript. Each sample

was quantified in triplicate.

Statistical Analysis

We displayed data as mean $\pm$ standard deviation (SD) across patients in scatter plots using GraphPad Prism. We analyzed the data with one-way analysis of variance (ANOVA) and Tukey's multiple-comparison test in GraphPad Prism. Asterisks (*) indicate rising levels of statistical significance ($p < 0.05$), whereas "ns" indicates non-significant data ($p > 0.05$). The associations among the KL, CAT, and SOD1 genes were evaluated using Pearson correlation coefficients (r) and corresponding p -values, which were presented in a matrix scatter plot.

RESULTS

Demographic parameters

The study included a total of 150 participants: 108 with CKD, 15 with AKI, and 27 healthy controls (Figure 1). Among 108 CKD patients, 9 were classified as CKD stage 2, while 12, 21, and 66 were categorized as CKD stage 3, 4, and 5, respectively, as shown in Figure 2. The mean age of cases (kidney disease patients) was 45 ± 15 years, while controls had a mean age of 42 ± 15 years. In the cases, 59% were male, and 36% were female, while in the control group, 60% were male and 40% were female. The research highlights the demographic parameters within the studied groups.

Genetic expression among AKI and CKD

Oxidative stress plays a role in the development of atherosclerosis and the advancement of renal damage in patients with kidney disease. The expression levels of the *KL*, *CAT*, *SOD1*, *p53*, and *CyPA* genes help elucidate the pathogenesis of CKD and AKI. The relative expression levels of *KL* and *CAT* were significantly downregulated ($p < 0.0001$) in CKD and AKI patients compared with controls. In contrast, *SOD1* was 1.5-fold upregulated in AKI patients and downregulated in CKD patients compared with controls, as shown in Figure 1. The expression levels of *p53* were significantly ($p < 0.001$) upregulated by > 6 -fold and > 3 -fold in CKD patients and AKI patients, respectively, compared to controls (Figure 1e). *CyPA* was significantly upregulated by > 1.5 -fold and > 2 -fold in CKD and AKI patients, respectively ($p < 0.0001$; Figure 1f). Further, the relative expression of the *CAT*, *SOD1*, and *CyPA* genes was higher in AKI patients than in CKD patients. Overall, these results indicate downregulation of *KL*, *CAT*, and *SOD1*, and upregulation of *p53* and *CyPA*, suggesting progressive kidney damage and an activated cellular stress response in kidney disease patients.

The mean values were normalized to *GAPDH* = . SD is indicated by the error bar, and the line indicates the means of each group. Ns = non-significant, asterisks (*) = statistically significant at the given probability level(s).




Figure 1: Relative transcript abundance of *KL*, *CAT*, *SOD1*, *p53* and *CyPA* genes




Figure 2: Relative transcript abundance of KL, CAT, SOD1, p53 and CyPA genes across CKD stages

Genetic expression among CKD stages

As shown in **Figure 1**, the expression levels of the *KL*, *CAT*, *SOD1*, *p53*, and *CyPA* genes were disturbed; therefore, their levels were further investigated across CKD stages. In a stage-wise distribution, the expression of the *KL* and *CAT* genes was downregulated in all CKD stages compared to controls, as shown in **Figure 2**. The relative expression levels of the *SOD1* gene were similar to those of controls (**Figure 2c**). *p53* levels of *p53* were significantly upregulated (>9-fold, 6-fold, >3-fold, and >1-fold) across CKD stages (stage 5 to stage 2) compared to control, as shown in **Figure 2e**. The level of *CyPA* was significantly upregulated (>1.8-fold) in CKD stages 5 and 4 compared to the control. In contrast, it was significantly different from the control in CKD stages 3 and 2, as shown in **Figure 2f**. Overall, these results indicate that downregulation of *KL*, *SOD1*, and *CAT*, along with upregulation of *p53* and *CyPA* in CKD stages, suggests reduced antioxidant defense and heightened cellular stress, peaking in stages 4 and 5.

Mean values were normalized to *GAPDH*. SD is indicated by the error bar, and the line indicates the means of each group. Ns = non-significant, asterisks (*) = statistically significant at the given probability level(s).

Correlation among KL, CAT, and SOD1 genes

The genetic correlation can help to understand the causality of relationships among genes. Therefore, the correlations of *KL*, *CAT*, and *SOD1* were examined to understand their relationships. **Table II** presents the gene expression relationships within the control subgroup, focusing on *KL*, *CAT*, and *SOD1*. Correlation coefficients (*r*) and *p*-values are provided, revealing potential associations between these gene expressions. The correlations reveal several noteworthy patterns. ***Klotho-F*** exhibits a positive correlation with ***Catalase*** (*r* = 0.195), indicating limited association, as shown in **Figure 3**. These correlations provide initial insights into potential connections between the examined gene expressions among cases. The *p*-values indicate that the significance of these correlations varies across pairs. Notable correlations may suggest shared regulatory mechanisms or potential interactions among these gene expressions. Further research and analysis are needed to clarify the biological significance of these correlations and their potential implications in the context of kidney health and disease. Among the cases, *Klotho* showed a weak but significant positive correlation with *catalase*. No significant correlation was seen between *Klotho* and *SOD-1*. Similarly, no significant correlation was observed between *catalase* and *SOD-1* (**Figure 3**). Therefore, the *KL* gene was

positively correlated with the CAT gene, but SOD-1 showed no association with KL or CAT.

Table II: Correlation of gene expression of KL, CAT, and SOD1 among kidney disease patients

		KL	CAT	SOD1
KL	r	-	0.195	0.063
	p-value		0.026	0.478
CAT	r		-	0.159
	p-value			0.071
SOD1	r			-
	p-value			

Note: r: Correlation coefficient, n: number

DISCUSSION

Chronic Kidney Disease (CKD) is a progressive disorder characterized by irreversible/permanent loss of kidney function, frequently associated with molecular and cellular alterations.¹⁵ Understanding the underlying genetic mechanisms is critical for elucidating disease progression. In the present study, we investigated the differential expression of KL, CAT, SOD1, p53, and CyPA genes to understand the pathogenesis in kidney disease patients across CKD, AKI and control groups. The expression patterns may indicate oxidative burden and cellular compensatory responses in renal tissues.

Hassan MH et al.¹⁵ reported lower Klotho levels in AKI and CKD patients than in controls, consistent with our study. Further, our study found lower expression in AKI versus CKD (**Figure 1b**). Shimamura Y et al.¹⁶ found that serum klotho levels were lower in patients with CKD stages 2 to 5 than in stage 1 patients, consistent with our study, which shows downregulation of the KL gene in CKD stages 3 to 5 versus stage 2 (**Figure 2b**). Devaraj S 2012¹⁷ found elevated klotho levels in CKD patients, which is

contrary to our study; this may be because CKD was identified as a creatinine level of more than 2 mg/dL over 12 months in their study, while in our study, CKD was identified by the MDRD equation according to KDIGO guidelines. The age of the patients were much older (median age 54 years) than in our study. Age has a major impact on levels of an anti-ageing protein⁹. Further, the small sample size may limit the generalizability of their findings to the entire CKD population.

Sulaiman SH 2021¹⁸ reported that OS strongly influences cellular and tissue damage in AKI and CKD patients and found significantly lower CAT activities in CKD and AKI patients than in controls, findings consistent with our study (**Figure 1c**). Further, our study found that the CAT gene is downregulated in CKD and AKI patients, particularly in CKD stages 4 and 5 compared with stages 2 and 3 (**Figure 2c**). Catalase protects kidneys from oxidative stress; loss of its activity leads to fibrosis and progressive renal injury^{7,8}. Our study found that KL was positively correlated with CAT (**Figure 3**). No contrary data were found. Pathare G 2020¹⁹ reported lower levels of KL and CAT in hypertensive patients than in controls. They reported a positive correlation between CAT and KL, which is somewhat consistent with our study of kidney disease participants.

Our study observed SOD1 gene downregulation in CKD patients and upregulation in AKI patients (**Figure 1d**).

Sulaiman SH 2021¹⁸ found significantly lower SOD activity in CKD and reported that oxidative stress strongly influences cellular and tissue damage in AKI and CKD patients, consistent with our study. Scholze A et al.²⁰ reported significantly higher SOD1 gene expression in CKD patients than in controls, which contrasts with our findings. Increased SOD1 gene expression may reflect enhanced protein degradation




Figure 3: Correlation of KL, CAT, and SOD1 genes in relation to severity of disease among AKI and CKD (A) and CKD stages (B)

in CKD patients²⁰. Sulaiman SH 2021¹⁸ reported significantly lower SOD activity in AKI patients than in controls, which contrasts with our study; this may be due to increased antioxidative defense or a small sample size in our study.

Ye Z et al.²¹ found that expression of p53 was increased in patients with CKD, consistent with our study. Our study also indicated that p53 gene expression is significantly higher in CKD patients than in AKI patients (**Figure 1e**). Additionally, p53 levels increase progressively with CKD stages, with the greatest upregulation observed in stages 4 and 5 compared with stages 2 and 3 (**Figure 2e**). No contrary data were found. Zhen X et al.²² reported that the accumulation of Nicotinamide N-methyltransferase (NNMT) in CKD may reduce p53 methylation while increasing p53 expression and activity.

Ming WH et al.²³ study showed that p53 regulates Wnt7a expression through transcription, activates the Wnt/ β -catenin signalling pathway in UUO and adenine-induced renal fibrosis models, and participates in the process of renal fibrosis. Wnt9a significantly upregulated the levels of ageing-related p16, p19, p53, and p21, promoting renal fibrosis in humans²⁴. These studies show the association of p53 with the Wnt/ β -catenin signaling pathway. Therefore, in CKD, p53 enhances Wnt/ β -catenin signaling, which, in turn, increases p53 expression^{23,24}. Lee C-C et al.²⁵ found that circulating eCyPA and uCyPA levels markedly increase in AKI. Similarly, Chatchawal et al.²⁶ found increased uCypA in patients with progression of renal deterioration, specifically in the diabetes with late-stage CKD group, compared with controls. These studies are consistent with our study.

In this study, the CyPA gene was upregulated in CKD and AKI patients compared with controls, with higher expression in AKI than in CKD (**Figure 1f**). Chatchawal P et al.²⁶ reported elevated uCypA levels in patients with early-stage CKD. In contrast, in our study, the level of CypA in early-stage CKD was similar to those in controls (**Figure 2f**). The Chatchawal P et al.²⁶ study measured CypA protein (reduced clearance), whereas in our study, mRNA levels were measured. Despite growing evidence that oxidative stress and cellular defence mechanisms play a central role in CKD, local data are lacking, and global findings on the expression of KL, CAT, SOD1, p53, and CyPA genes are inconsistent. Previous studies have reported variable expression trends, with some indicating upregulation and others showing marked downregulation during disease progression. These discrepancies, likely influenced by study design, disease stages, and methodological variations, limit our understanding of their true role in CKD pathogenesis. Ultimately, this study bridges molecular insights and clinical management by elucidating the expression patterns of genes involved in OS regulation and renal protection. Therefore, these findings highlight the involvement of these genes in the complex interplay of oxidative stress and

cellular regulation, offering new insights into CKD pathogenesis and paving the way for innovative diagnostic and therapeutic strategies.

CONCLUSION

The relative expression of *KL*, *CAT*, *SOD1*, *p53* and *CyPA* genes reveals their crucial role in modulating OS during the pathogenesis of CKD. Their expression across advancing CKD stages suggests impaired antioxidant defense mechanisms, contributing to renal damage and disease progression. These findings underscore the potential of these genes as biomarkers for CKD severity and as therapeutic targets to mitigate OS and preserve kidney function.

Ethical permission: Multan Medical & Dental College, Multan, Pakistan, IRB/IEC approval letter No. C-29-970.

Conflict of interest: There is no conflict of interest between the authors.

Financial Disclosure / Grant Approval: No funding agency was involved in this research.

Data Sharing Statement: The corresponding author can provide the data proving the findings of this study on request. Privacy or ethical restrictions bound us from sharing the data publicly.

AUTHOR CONTRIBUTION

Farooq B: Conceived, designed the study, collected data and finalized the manuscript.

Iqbal M: Assisted in patient recruitment and reviewed the manuscript for accuracy.

Jaffar M: Coordinated analysis and contributed to the literature review.

Qureshi ZH: Data management and formal analysis.

Faisal M: Conducted experiments, data and statistical analyses, and manuscript writing.

Lodhi MS: Conception, experimental design, and data analysis.

REFERENCES

1. Liu P, Quinn RR, Lam NN, Elliott MJ, Xu Y, James MT et al. Accounting for age in the definition of chronic kidney disease. *JAMA Intern Med.* 2021; 181(10): 1359-66.
2. Quadri MM, Fatima S-S, Che R-C, Zhang A-H. Mitochondria and renal fibrosis. *Renal Fibrosis: Mechanisms and Therapies. Adv Exp Med Biol.* 2019:501-24.
3. He L, Wei Q, Liu J, Yi M, Liu Y, Liu H et al. AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. *Kidney Int.* 2017; 92(5): 1071-83.
4. Thérond P, Bonnefont-Rousselot D, Davit-Spraul A, Conti M, Legrand A. Biomarkers of oxidative stress: an analytical approach. *Curr Opin Clin Nutr Metab Care*, 2000; 3(5): 373-84.
5. Donate-Correa J, Martín-Carro B, Cannata-Andía JB, Mora-Fernández C, Navarro-González JF.

- Klotho, oxidative stress, and mitochondrial damage in kidney disease. *Antioxidants*, 2023; 12 (2): 239.
6. Tirichen H, Yaigoub H, Xu W, Wu C, Li R, Li Y. Mitochondrial reactive oxygen species and their contribution in chronic kidney disease progression through oxidative stress. *Front Physiol*. 2021; 12: 627837.
 7. Hong YA, Park CW. Catalytic Antioxidants in the Kidney. *Antioxidants*, 2021; 10(1).
 8. Carmo de Carvalho e Martins, da Silva Santos Oliveira AS, da Silva LAA, Primo MGS, de Carvalho Lira VB. Biological indicators of oxidative stress [malondialdehyde, catalase, glutathione peroxidase, and superoxide dismutase] and their application in nutrition. *Biomarkers in nutrition*: Springer; 2022; 833-56.
 9. Sakan H, Nakatani K, Asai O, Imura A, Tanaka T, Yoshimoto S et al. Reduced renal α -Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. *PLoS One*, 2014; 9(1): e86301.
 10. Capuozzo M, Santorsola M, Bocchetti M, Perri F, Cascella M, Granata V, et al. p53: from fundamental biology to clinical applications in cancer. *Biol*. 2022; 11(9): 1325.
 11. Chinnam M, Xu C, Lama R, Zhang X, Cedeno CD, Wang Y et al. MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity. *PLoS Genet*. 2022; 18(5): e1010171.
 12. Ye Z, Xia Y, Li L, Li B, Chen L, Yu W, et al. p53 deacetylation alleviates calcium oxalate deposition-induced renal fibrosis by inhibiting ferroptosis. *Biomed Pharmacother*. 2023; 164: 114925.
 13. Hadpech S, Thongboonkerd V. Current update on theranostic roles of cyclophilin A in kidney diseases. *Theranostics*, 2022; 12(9): 4067.
 14. Yang W-C, Hsieh H-M, Chen J-P, Liu L-C, Chen C-H. Effects of a low-protein nutritional formula with dietary counseling in older adults with chronic kidney disease stages 3–5: a randomized controlled trial. *BMC Nephrol*. 2023; 24(1): 372.
 15. Hassan MH, Saleem TH, Abdallah AAM, Abdelhady M, Salama DA-E, Elsaied AA et al. Expression profile of FGF23, α klotho, microRNA-126, and wnt signaling pathway gene polymorphism in patients with acute or chronic kidney diseases: relation to dialysis requirements. *Egypt J Intern Med*. 2025; 37(1): 5.
 16. Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, Kagawa T et al. Serum levels of soluble secreted α -Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. *Clin Exp Nephrol*. 2012; 16(5): 722-729.
 17. Devaraj S, Syed B, Chien A, Jialal I. Validation of an immunoassay for soluble Klotho protein: decreased levels in diabetes and increased levels in chronic kidney disease. *Am J Clin Pathol*. 2012; 137(3): 479-485.
 18. Sulaiman SH, Demir H, Soyoral YU, Demir C. Determination of oxidative stress levels and some antioxidant activities in acute and chronic renal failure patients. *J Clin Chem Lab Med*. 2021; 7(1): 12-29.
 19. Pathare G, Raju S, Mashru M, Shah V, Shalia K. α -Klotho and catalase expression in essential hypertension. *Integr Mol Med*. 2020; 7: 1-6.
 20. Scholze A, Krueger K, Diedrich M, R  th C, Torges A, Jankowski V et al. Superoxide dismutase type 1 in monocytes of chronic kidney disease patients. *Amino Acids*, 2011; 41(2): 427-438.
 21. Ye Z, Xia Y, Li L, Li B, Chen L, Yu W et al. p53 deacetylation alleviates calcium oxalate deposition-induced renal fibrosis by inhibiting ferroptosis. *Biomed. Pharmacother*. 2023; 164: 114925.
 22. Zhen X, Sun Y, Lin H, Huang Y, Liu T, Li Y et al. Elucidating the role of nicotinamide N-methyltransferase-p53 axis in the progression of chronic kidney disease. *PeerJ*. 2023; 11: e16301.
 23. Ming WH, Wen L, Hu WJ, Qiao RF, Zhou Y, Su BW et al. The crosstalk of Wnt/ β -catenin signaling and p53 in acute kidney injury and chronic kidney disease. *Kidney Res Clin Pract*. 2024; 43(6): 724-38.
 24. Luo C, Zhou S, Zhou Z, Liu Y, Yang L, Liu J et al. Wnt9a promotes renal fibrosis by accelerating cellular senescence in tubular epithelial cells. *J Am Soc Nephrol*. 2018; 29(4): 1238-56.
 25. Lee C-C, Chang C-H, Cheng Y-L, Kuo G, Chen S-W, Li Y-J et al. Diagnostic performance of cyclophilin a in cardiac surgery-associated acute kidney injury. *J Clin Med*. 2019; 9(1): 108.
 26. Chatchawal P, Tippayawat P, Somdee T, Ngermpimai S, Wongwattanukul M, Sae-ung N, et al. Urinary cyclophilin A as an early marker of chronic kidney disease with underlying type 2 diabetes. *Sci Rep*. 2024; 14(1): 23207.

